ClinicalTrials.gg
Active, not recruitingNCT05628207Updated Oct 2, 2026

Evaluation of the SCALED (SCaling AcceptabLE cDs)

An observational study in Traumatic Brain Injury and Venous Thromboembolism, sponsored by University of Minnesota. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University of Minnesota · Observational

How we know

Updated Oct 2, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
15,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 909 studies in Brain Injuries, Traumatic with a site in United States — 212 open to participants now, 250 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.

Planned enrollment
2nd of 257
15,000 · median 120
Started
2023
with 41 others
Observational
258 of 909
56 open now
Primary completion
2027-03
later than 101 of 249 live
Registered
708th of 909
by date

Among the 909 studies in Brain Injuries, Traumatic with a site in United States, this one is the 2nd largest by planned enrollment of the 257 observational ones that give a count, is one of 42 that started in 2023, is one of 258 observational ones, reaches primary completion later than 101 of the 249 other live ones, and was the 708th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

212 of the 909 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:

207 more — sign in →

All 212 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Brain Injuries, Traumatic with a site in United States, or all of them as a file.
02

Study summary

This project will adapt a currently deployed Clinical Decision Support (CDS) system to deliver a VTE prevention guideline for adult patients with traumatic brain injury (TBI). We believe this is an ideal PCOR use case given PCORI's continued effort to combat VTE in trauma and our experience previously implementing this guideline. The Our overall goal is to successfully scale, evaluate, and maintain an interoperable TBI CDS across 7 total institutions.

03

Conditions studied

  • Traumatic Brain Injury
  • Venous Thromboembolism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All patients age 18 and older admitted with a TBI will be eligible for inclusion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18 and older
  • admitted with a TBI

Exclusion criteria

Exclusion Criteria:

  • Patients who die within 24 hours of hospital admission and patients documented as "comfort cares" during the first 72 hours of hospitalization or with mild TBI will be excluded from final analysis.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
15,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • 4 hospitals using CDS TBI

    healthcare system leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.

    Other: Observational

  • 3 hospitals not using CDS TBI (control)

    healthcare system not leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.

    Other: Observational-control

Interventions

  • OtherObservational

    There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.

  • OtherObservational-control

    There is no intervention, the hospitals will not use the CDS system.

06

What researchers measure

Primary outcomes

  1. primary effectiveness outcome

    VTE event rate

    Time frame: 2 years and a half

  2. Evaluate implementation strategy guided by the EPIS Implementation

    the number of patients that received treatment according to the best practice guideline and the % adherence to the guideline per site

    Time frame: 2 years and a half

07

Study locations

1 site
08

References and documents

Publications

  • Tignanelli CJ, Shah S, Vock D, Siegel L, Serrano C, Haut E, Switzer S, Martin CL, Rizvi R, Peta V, Jenkins PC, Lemke N, Thyvalikakath T, Osheroff JA, Torres D, Vawdrey D, Callcut RA, Butler M, Melton GB. A pragmatic, stepped-wedge, hybrid type II trial of interoperable clinical decision support to improve venous thromboembolism prophylaxis for patients with traumatic brain injury. Implement Sci. 2024 Aug 5;19(1):57. doi: 10.1186/s13012-024-01386-4. PubMed 39103955 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Mar 2027, 45 months after the start.

Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 45 months is close to that.

Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Sep 2026 → Mar 2027 and completion Sep 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Nov 28, 2022
StartActual
May 16, 2023
Primary completionEst.
Mar 1, 2027was Sep 2026
CompletionEst.
Mar 1, 2027was Sep 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Primary completion
Sep 30, 2026→Mar 1, 2027
Oct 2, 2026
Study completion
Sep 30, 2026→Mar 1, 2027
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 30, 2026→Mar 1, 2027
    Study completion Sep 30, 2026→Mar 1, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05628207
Collaborators
Agency for Healthcare Research and Quality (AHRQ)
Responsible party
Sponsor
First posted
Nov 28, 2022
Start date
May 16, 2023
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion